Jeffrey Grover
About Jeffrey Grover
Jeffrey Grover is a Senior Scientist I specializing in NGS and Bioinformatics at Entrada Therapeutics in Boston, Massachusetts. He has extensive experience in molecular biology, having previously held positions at various institutions and earned a Ph.D. from the University of Arizona.
Work at Entrada Therapeutics
Jeffrey Grover has been employed at Entrada Therapeutics since 2024, currently holding the position of Senior Scientist I in NGS and Bioinformatics. His role involves leading projects related to RNA sequencing and bioinformatics. Prior to his current position, he served as Scientist II in the same department from 2022 to 2024. During his tenure, he has contributed to the development of computational infrastructure and data storage strategies, as well as standardizing RNA sequencing workflows. He has also implemented methods for pseudobulk differential expression in single-cell RNAseq analysis.
Education and Expertise
Jeffrey Grover earned a Doctor of Philosophy (Ph.D.) in Molecular and Cellular Biology from the University of Arizona, completing his studies from 2015 to 2020. He also holds a Professional Science Masters (PSM) in the same field from the University of Arizona, which he obtained from 2013 to 2015. Earlier, he completed a Bachelor of Science (B.S.) in Biochemistry & Molecular Biology and Chemistry at Michigan State University from 2007 to 2011. His educational background provides a strong foundation for his expertise in bioinformatics and genomics.
Background
Before joining Entrada Therapeutics, Jeffrey Grover held various positions in research and academia. He worked as a Genomics Scientist at Seven Bridges from 2020 to 2022, and as a Laboratory Assistant at Michigan State University from 2007 to 2011. He also gained experience as a Research Associate at MPI Research from 2011 to 2013 and as a Graduate Assistant at the University of Arizona from 2014 to 2020. Additionally, he briefly worked as a Laboratory Assistant at the University of Notre Dame in 2008.
Achievements
During his career, Jeffrey Grover has designed in-vitro and in-vivo experiments to assess organ-specific toxicity of drug candidates using RNA sequencing techniques. At Entrada Therapeutics, he led the transcriptomic characterization of the toxicity profile of a novel class of protein-conjugated oligonucleotide therapeutics. His work has contributed to advancements in RNAseq methodologies and the establishment of standardized workflows for both bulk and single-cell RNA sequencing.